LogicBio Therapeutics (LOGC)

Overall impact
B (72)

Commentary

LogicBio Therapeutics is a strong overall performer. With a 'B' rating of 72.3 for overall impact (85th percentile compared to all companies), LogicBio Therapeutics ranks 17th out of 76 industry peers, behind IMAC, Avedro, AnPac Bio-Medical Science and 13 others, and ahead of Enzo Biochem, Invitae, Check-Cap and 56 others. On top material causes for LogicBio Therapeutics's industry (Healthcare Software & Services), LogicBio Therapeutics performs well in Child and Maternal Health (84.5 score), Child and Maternal Health (88.4), Disease Eradication (96.3) and 4 other causes where it received an 'A' score and performs poorly in Reduced Green House Gas Emissions (31.2 score), Accountable Institutions (33.1) and Quality Lifelong Education (31.2).
Impact
Cause LOGC
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
4
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ca, United States
Share classes
LOGC
Description
ContextLogic Inc. does not have significant operations. It focuses on identifying, evaluating, and executing strategic opportunities. Previously, it was engaged in the marketplace and logistics business operations. ContextLogic Inc. was incorporated in 2010 and is headquartered in Oakland, California.
Material causes
Ethos considers the following causes material for LogicBio Therapeutics, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.